CVMP: Vaccine variations and authorisation extensions
The CVMP supported changes to Syvazul BTV 3, Hepizovac and Orbyk EHD and extensions for two avian influenza vaccines.
Overview
On 6 November 2026 EMA reported positive CVMP opinions on three veterinary vaccine variations and two extensions of authorisations under exceptional circumstances.
Syvazul BTV 3
The variation addresses two specific obligations: completion of an ELISA potency test for the BTV 3 antigen and submission of a study on duration of immunity in sheep.
Hepizovac
The opinion concerns stability studies up to 21 months to confirm the accepted 18-month shelf life of the finished product under recommended storage conditions.
Orbyk EHD
The variation addresses the complete validation report for the finished-product potency test and potency data supporting a 10-hour in-use shelf life.
Avian influenza
The CVMP recommended extending the validity of the authorisations under exceptional circumstances for Vaxxinact H5 and Vaxxitek HVT+IBD+H5 by one year each.
Regulatory interpretation and practice
These are product-specific procedures, not a new general vaccine guideline. Manufacturers should review outstanding obligations, potency methods, stability programmes and regulatory documentation. Legally effective implementation should be checked against the relevant formal decisions.
Official primary source
EMA: CVMP Meeting Highlights, 3–5 November 2026 (published 6 November 2026)
As of 13 November 2026. Scientific interpretation; official source documents take precedence.
